Top Back to top

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Myelodysplastic (MDS) or MDS/MPN
Short title:
Primary objective:
To evaluate the impact of additional adverse cytogenetic abnormalities on relapse-free survival after allo-SCT in MDS with very poor risk cytogenetics.
Key inclusion criteria:
 CR1, CR2 and beyond
 Age >= 18
 MDS with more than 3 cytogenetic abnormalities at diagnosis
 First allogeneic SCT
 Allogeneic SCT from matched family or matched unrelated donor between 2000 and 2016
Principal investigator:
Xavier Poiré
EBMT Study coordinator:
Linda Koster
Study coordinator email: